1. [1] Patocka J, Splino M. Anthrax toxin characterization. Acta Medica (Hradec Kralove) 2002; 45: 3-5.‏ [DOI:10.14712/18059694.2019.49]

2. [2] Bartlett JG, Inglesby TV Jr, Borio L. Management of anthrax. Clin Infect Dis 2002; 35: 851-858. [DOI:10.1086/341902] [PMID]

3. [3] Flick-Smith HC, Eyles JE, Hebdon R, Waters EL, Beedham RJ, Stagg TJ, Williamson ED. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun 2002; 70: 2022-2028. https://doi.org/10.1128/IAI.70.4.2022-2028.2002 [DOI:10.1128/IAI.70.3.1653-1656.2002] [PMID] [PMCID]

4. [4] Chichester JA, Musiychuk K, de la Rosa P, Horsey A, Stevenson N, Ugulava N, Yusibov, V. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 2007; 25: 3111-3114. [DOI:10.1016/j.vaccine.2007.01.068] [PMID]

5. [5] Hepburn MJ, Dyson EH, Simpson AJ, Brenneman KE, Bailey N, Wilkinson L, Baillie LW. Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine. Vaccine 2007; 25: 6089-6097. [DOI:10.1016/j.vaccine.2007.05.018] [PMID]

6. [6] Wei Y, Wang Y, Kang A, Wang W, Ho SV, Gao J, Su Z. A novel sustained-release formulation of recombinant human growth hormone and its pharmacokinetic, pharmacodynamic and safety profiles. Mol Pharm 2012; 9: 2039-2048. [DOI:10.1021/mp300126t] [PMID]

7. [7] Zhang Y, Wu X, Han Y, Mo F, Duan Y, Li S. Novel thymopentin release systems prepared from bioresorbable PLA-PEG-PLA hydrogels. Int J Pharm 2010; 386: 15-22. [DOI:10.1016/j.ijpharm.2009.10.045] [PMID]

8. [8] Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 2011; 3: 1377-1397. [DOI:10.3390/polym3031377] [PMID] [PMCID]

9. [9] Des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006; 116: 1-27. [DOI:10.1016/j.jconrel.2006.08.013] [PMID]

10. [10] Donati C, Rappuoli R. Reverse vaccinology in the 21st century: improvements over the original design. Ann N Y Acad Sci 2013; 1285: 115-132. [DOI:10.1111/nyas.12046] [PMID]

11. [11] Moyle PM. Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines. Biotechnol Adv 2017; 35: 375-389. [DOI:10.1016/j.biotechadv.2017.03.005] [PMID]

12. [12] Albrecht MT, Li H, Williamson ED, LeButt CS, Flick-Smith HC, Quinn CP, Groen H. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun 2007; 75: 5425-5433. [DOI:10.1128/IAI.00261-07] [PMID] [PMCID]

13. [13] Nguyen ML, Crowe SR, Kurella S, Teryzan S, Cao B, Ballard JD, Farris AD. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies. Infect Immun 2009; 77: 162-169. [DOI:10.1128/IAI.00788-08] [PMID] [PMCID]

14. [14] Ghasemi R, Abdollahi M, Zadeh EE, Khodabakhshi K, Badeli A, Bagheri H, et al. mPEG-PLA and PLA-PEG-PLA nanoparticles as new carriers for delivery of recombinant human Growth Hormone (rhGH). Scientific Rep 2018; 8: 9854. [DOI:10.1038/s41598-018-28092-8] [PMID] [PMCID]

15. [15] Singh N, Mandal AK, Ahmed Khan Z. Fabrication of PLA-PEG nanoparticles as delivery systems for improved stability and controlled release of catechin. J Nanomaterials 2017; 1-9. [DOI:10.1155/2017/6907149]

16. [16] Mosayebi G, Abtahi H, Ghazavi A, Zareinfar N. Design of enzyme-linked immunosorbent assay method for detection of anti-streptolysin-O antibodies on base of recombinant streptolysin-O. Koomesh J 2012; 13: 362-367. (Persian).

17. [17] Brey RN. Molecular basis for improved anthrax vaccines. Adv Drug Deliv Rev 2005; 57: 1266-1292. [DOI:10.1016/j.addr.2005.01.028] [PMID]

18. [18] Bell M. DNA vaccine protects against anthrax. Am Soc Microbiol Biodefense Res Meet Baltimore. 2004.

19. [19] McComb RC, Martchenko M. Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen-the first step toward a rationally designed anthrax vaccine. Vaccine 2016; 34: 13-19. [DOI:10.1016/j.vaccine.2015.11.025] [PMID]

20. [20] Baillie LW, Huwar TB, Moore S, Mellado-Sanchez G, Rodriguez L, Neeson BN, Altmann DM. An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor. Vaccine 2010; 28: 6740-6748. [DOI:10.1016/j.vaccine.2010.07.075] [PMID] [PMCID]

21. [21] Makam SS, Kingston JJ, Harischandra MS, Batra HV. Protective antigen and extractable antigen 1 based chimeric protein confers protection against Bacillus anthracis in mouse model. Mol Immunol 2014; 59: 91-99. [DOI:10.1016/j.molimm.2014.01.012] [PMID]

22. [22] Rezaee M, Honari H, Kooshk MR. Cloning, expression and purification of binding domains of lethal factor and protective antigen of Bacillus anthracis in Escherichia coli and evaluation of their related murine antibody. Mol Biol Rep 2014; 41: 2445-2452. [DOI:10.1007/s11033-014-3099-4] [PMID]

23. [23] Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immu 2001; 69: 4509-4515. [DOI:10.1128/IAI.69.7.4509-4515.2001] [PMID] [PMCID]

24. [24] Wu G, Hong Y, Guo A, Feng C, Cao S, Zhang CC, Liu Z. A chimeric protein that functions as both an anthrax dual-target antitoxin and a trivalent vaccine. Antimicrob Agents Chemother 2010; 54: 4750-4757. [DOI:10.1128/AAC.00640-10] [PMID] [PMCID]

25. [25] Makam SS, Kingston JJ, Harischandra MS, Batra HV. Protective antigen and extractable antigen 1 based chimeric protein confers protection against Bacillus anthracis in mouse model. Mol Immunol 2014; 59: 91-99. [DOI:10.1016/j.molimm.2014.01.012] [PMID]

26. [26] Shcherbinin DN, Esmagambetov IB, Noskov AN, Tutykhina IL, Shmarov MM, Logunov DY, Gintsburg AL. Protective immune response against Bacillus anthracis induced by intranasal introduction of a recombinant adenovirus expressing the protective antigen fused to the Fc-fragment of IgG2a. Acta Natur 2014; 6: 20. https://doi.org/10.32607/20758251-2014-76-84 [DOI:10.32607/20758251-2014-6-1-76-84]

27. [27] Varshney A, Puranik N, Kumar M, Goel AK. Immunogenecity of a chimeric protein of Bacillus anthracis protective antigen and lethal factor in murine model. Int J Infect Dis 2016; 45: 426. https://doi.org/10.1016/j.ijid.2016.02.907 [DOI:10.1016/j.ijid.2016.02.906]

28. [28] Abdous M, Hasannia S, Salmanian AH, Shahryar Arab S, Shali A, Alizadeh GA, Mohseni A. A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses. Immunopharmacol Immunotoxicol 2018; 1-7. [DOI:10.1080/08923973.2018.1510419] [PMID]